Latvia’s Ministry of Finance has revised its 2026 economic growth forecast upward to 2.4%, marking a 0.4 percentage point increase from June estimates. Driven by a stronger-than-expected first half where GDP expanded 2.8% year-over-year, the upward revision comes despite ongoing geopolitical volatility and tightening labor markets across the Baltic region.
The Bottom Line
- GDP Revision: Full-year 2026 real GDP growth is now pegged at 2.4%, supported by solid retail trade, manufacturing, and commercial services performance in H1.
- Inflation Cooling: The 2026 annual inflation projection was trimmed by 0.2 percentage points to 3.4%, heavily aided by food price deflation reaching 3-4%.
- Persistent Headwinds: Ministries and institutional observers warn of substantial downside risks, including escalating Middle East tensions, Hormuz Strait disruptions, and lingering structural bottlenecks in transport and logistics.
Navigating H1 Outperformance Amid Global Friction
Here is the math: despite external shocks, real GDP during the first half of the year climbed 2.8% compared to the same period in 2025.
That momentum was broad-based. Trade, industrial manufacturing, and commercial service sectors drove the lion’s share of value-added output. From an expenditure perspective, recovering private consumption, capital investment increases, and a noticeable acceleration in exports from the second quarter onward kept corporate balance sheets resilient. But the balance sheet tells a different story when looking out past the immediate horizon.
Macroeconomic Indicators at a Glance
| Indicator | 2026 (Revised) | 2027 (Projected) | 2030 (Medium-Term Target) |
|---|---|---|---|
| Real GDP Growth | 2.4% | 1.9% | 2,0-2,4% |
| Average Annual Inflation | 3.4% | 3,7% | 2.2% |
| Unemployment Rate | 6.8% | 6.5% | 6.1% |
| Average Monthly Wage Growth | 5.0% | 5,5% | Aligned with Productivity |
Inflation Dynamics and Wage Pressures
Price stability has provided unexpected breathing room for households. This deceleration stems primarily from food price stabilization and recent value-added tax adjustments, driving annual food deflation down by 3-4%.
However, delayed pass-through effects remain a clear hazard for corporate treasuries. Subsequent spikes in global crude oil and natural gas prices, alongside lagging increases in district heating tariffs, forced authorities to nudge inflation forecasts upward for the following two years to 3,7% in 2027. Meanwhile, nominal wage growth has decelerated significantly. Average monthly gross wages climbed 4.6% in the year’s first half, constrained heavily by public sector spending caps where wage growth slowed to 3.4%. Consequently, overall 2026 wage growth projections have been pulled down to 5.0%.
Downside Risks and Medium-Term Outlook
For institutional allocators monitoring the Baltic perimeter, the Fiscal Discipline Council approved these updated parameters on September 10, 2026, against a backdrop of pronounced external vulnerability. Geopolitical flashpoints—specifically conflicts involving the Strait of Hormuz, ongoing hostilities in Ukraine, and heightened security incidents across Europe—introduce structural risk to energy supply chains.
Domestically, high uncertainty persists in the transport sector, notably within rail and aviation networks, alongside potential delays in absorbing European Union structural funds. While structural demographic headwinds will steadily reduce the working-age population—pushing long-term unemployment down toward 6.1% by 2030—the immediate economic trajectory remains hostage to external commodity shocks and global financial market volatility.
Keep reading
- Roche Stock Rises as Tam-Peli Extends Lung Cancer Survival in Phase III Study
- Dollar Strengthens as Treasury Yields Rise Amid Inflation Fears
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)
